Short Interest in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Grows By 498.5%

Key Points

• Short interest in Barinthus Biotherapeutics PLC surged by 498.5%, increasing from 13,400 shares at the end of August to 80,200 shares by September 15th.
• HighTower Advisors LLC acquired a new position in Barinthus Biotherapeutics, purchasing 37,450 shares valued at approximately $36,000, reflecting growing institutional interest.
• The company's stock performance revealed a twelve-month high of $2.92 and a low of $0.64, indicating significant volatility in price.

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS - Get Free Report) was the target of a large increase in short interest in September. As of September 15th, there was short interest totaling 80,200 shares, an increase of 498.5% from the August 31st total of 13,400 shares. Based on an average trading volume of 1,210,000 shares, the short-interest ratio is currently 0.1 days. Approximately 0.2% of the shares of the stock are short sold. Approximately 0.2% of the shares of the stock are short sold. Based on an average trading volume of 1,210,000 shares, the short-interest ratio is currently 0.1 days.

Institutional Trading of Barinthus Biotherapeutics

An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. HighTower Advisors LLC purchased a new stake in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 37,450 shares of the company's stock, valued at approximately $36,000. HighTower Advisors LLC owned approximately 0.09% of Barinthus Biotherapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 25.20% of the company's stock.

Barinthus Biotherapeutics Stock Performance

Shares of Barinthus Biotherapeutics stock opened at $1.25 on Wednesday. The firm's 50-day simple moving average is $1.26 and its 200-day simple moving average is $1.05. Barinthus Biotherapeutics has a twelve month low of $0.64 and a twelve month high of $2.92. The firm has a market cap of $50.90 million, a P/E ratio of -0.72 and a beta of -0.75.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.23). On average, equities analysts forecast that Barinthus Biotherapeutics will post -1.38 earnings per share for the current fiscal year.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.